Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone

Journal of Steroid Biochemistry and Molecular Biology

Volumn 116, Issue 3-5, 2009, Pages 187-190

  Nishino, Tsuyuki ^a   Ishibashi, Kanako ^a   Hirtreiter, Christian ^a   Nishino, Yukishige ^a  

^a Research and Development   (Japan)

Author keywords

Antiprogestin; Antitumor effect; Onapristone; Rat; Tamoxifen

Indexed keywords

ANTIESTROGEN; ANTIGESTAGEN; LUTEINIZING HORMONE; MEGESTROL ACETATE; ONAPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HORMONE SYNTHESIS; NONHUMAN; OVARIECTOMY; OVARY; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; RAT; UPREGULATION; UTERUS WEIGHT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GONANES; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

ANIMALIA; RATTUS;

EID: 67650656656     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.05.013     Document Type: Article

References (24)

1. Nishino Y., Schneider M.R., and Michna H. Enhancement of the antitumor efficacy of antiprogestin, onapristone, by combination with antiestrogens. Fourth International Congress on Hormone and Cancer. Amsterdam (1991) 227 (abstract)
2. Nishino Y., Schneider M.R., and Michna H. Enhancement of the antitumor efficacy of antiprogestin, onapristone, by combination with antiestrogens. ICI 164384. J. Cancer Res. Clin. Oncol. 120 (1994) 298-302
3. Nishino Y., Schneider M.R., and Michna H. Enhancement of the antitumor effect of the aromatase inhibitor, atamestane by combination with the progesterone antagonist, onapristone in experimental breast cancer. J. Cancer Res. Clin. Oncol. 118 (1992) R112 (abstract no. V6.09.04)
4. Nishino Y., Schneider M.R., and Michna H. Potentiation of the antitumor effect by a combination of aromatase inhibitors and antiprogestins in experimental mammary tumor models. Folia Endocrinol. Jap. 68 (1992) 420 (abstract no. 654)
5. Schneider M.R., Michna H., Nishino Y., and El Etreby M.F. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and MNU-induced mammary tumor models of the rat. Eur. J. Cancer Clin. Oncol. 25 (1989) 691-701
6. Thomas M., and Monet J.D. Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of MCF-7 cell line. J. Clin. Endocrinol. Metab. 75 (1992) 865-870
7. Bakker G.H., Seytono-Han B., Portengen H., de Jong F.H., Foekens J.A., and Klijin J.G.M. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 125 (1989) 1593-1598
8. May F.E.B., Johnson M.D., Wieseman L.R., Wakeling A.E., Kastner P., and Westley R. Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. J. Steroid Biochem. 33 (1989) 1035-1041
9. Horwith K.B., Koseki Y., and McGuire W.L. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103 (1979) 1742-1751
10. Namer M., Lalanne C., and Baulieu E.E. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res. 40 (1980) 1750-1988
11. Waseda N., Kato Y., Imura H., and Kurata M. Effect of tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res. 41 (1981) 1984-1988
12. Noguchi S., Miyauchi K., Nishizawa Y., and Koyama H. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behaviour over time. Cancer 61 (1988) 1345-1349
13. Robustelli della cuna G., Pavesi L., and Preti P. Tamoxifien/medroxyprogesterone acetate sequential treatment for advanced breast cancer. Antioestrogens in oncology/past, present, and prospects. Excerpta Med. Int. Congr. Ser. 31 (1985) 182-197
14. Pouillart P., Palangie T., Jouve M., Garcia-Giralt E., Magdelenat H., and Martin P.M. Sequential administration of tamoxifen and medroxyprogesterone acetate. Bull. Cancer 69 (1982) 176-177
15. Asselin H., Kelley P.A., Caron M.G., and Labrie F. Control of hormone receptor levels and growth of 7,12-dimethylbenzanthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology 101 (1977) 666-671
16. Horwith K.B., and MacGuire W.L. Progesterone and progesterone receptors in experimental breast cancer. Cancer Res. 37 (1977) 1733-1738
17. Nishino Y., Parczyk P., Michna H., and Schneider M.R. Why are potent antiuterotrophic antiestrogens in contrast to antiprogestins weakly active in exerting antitumor effect on experimental mammary tumors?. 11th International Symposium of the "Journal of Steroid Biochemistry and Molecular Biology". Seefeld (1993) 16P (abstract)
18. Michna H., Gehring S., Kühnel W., Nishino Y., and Schneider M.R. The antitumor potency of progesterone antagonist is due to their differentiation potential. J. Steroid Biochem. Mol. Biol. 43 (1992) 203-210
19. Michna H., Nishino Y., Neef G., MacGuire W.L., and Schneider M.R. Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J. Steroid Biochem. Mol. Biol. 41 (1992) 339-348
20. Madjno R., Parczyk C., Michna H., and Schneider M.R. The impact of tamoxifen and the pure antiestrogen ZM 182780 on estrogen and progesterone receptor levels in rat mammary carcinoma and uterine tissue. Twelfth International Symposium of the Journal of Steroid Biochemistry and Molecular Biology. Berlin (1995) 39P (abstract)
21. Schubert C., Nishino Y., and Michna H. Ovulationshemmung durch Antigestagene: Korrelation mit endokrinen und follikulären Reaktionen. In: Kühnel W. (Ed). 89. Verhandlungen der Anatomischen Gesellschaft (1994), Gustav Fischer Verlag, Jena, Stuttgart, New York
22. Schubert C., Nishino Y., and Michna H. Ann. Anat. 176 Suppl. (1994) 270-271
23. Schubert C., Donath J., Michna H., and Nishino Y. The antiovulatory potency of progesterone antagonists due to their antiprogestational activity?. Exp. Clin. Endocrinol. 102 Suppl. 1 (1994) 91 (abstract no. 103)
24. Schubert C., Nishino Y., and Michna H. Disturbance of follicular development and endocrine reactions induced by the antiovulatory effective progesterone antagonist onapristone. Ann. Anat. 177 (1995) 139-146